Background
==========

About one million people are diagnosed with gastric carcinoma each year all over the world, making it the fourth most common cancer and the second leading cause of cancer related death \[[@B1]\]. The incidence rate of gastric carcinoma varies dramatically from one part of the world to another and it is particularly common in Eastern Asia, including China \[[@B2]\]. The prognosis for gastric adenocarcinoma patients remains poor and our understanding of this cancer entity is still limited.

According to the Lauren classification, gastric adenocarcinomas can be divided into two major histological types, diffuse and intestinal type \[[@B3]\]. The intestinal type is characterized by cohesive cells which form gland-like structures, while for the diffuse type, tumor cells lack cell-to-cell interactions and infiltrate the stroma as single cell or small subgroups, leading to a population of non-cohesive, scattered tumor cells \[[@B3]\]. Although the Lauren classification system can date back to 1965, it is still widely accepted and employed by pathologists and physicians today and represents a simple but robust classification approach. The two Lauren types have several distinct clinical and molecular characteristics, including etiology, carcinogenesis, epidemiology and progression, message ribonucleic acid (mRNA) and / or protein expression profile, microsatellite instability, and mutation profiles \[[@B4]\]. Thus, it is widely accepted that they represent distinct disease entities which may benefit from different therapeutic approaches. In the recent reported clinical trial---Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA), patients in the control group had a higher overall survival rates than expected \[[@B5]\] and the authors considered that it might be due to the higher percentage of intestinal-type tumors in the control group compared with other phase III studies \[[@B6]\]. It was reported that the expression of human epidermal growth factor receptor-2 (HER2) was more common in intestinal-type tumors and such patients have a better outcome than patients with diffuse-type tumors \[[@B7]-[@B10]\]. The importance of Lauren classification took our attention.

The aims of our present study are: (1) to analyze the prognostic value of Lauren classifications in resectable gastric cancer patients in China, (2) to compare the clinicopathological characteristics of diffuse-type and intestinal-type in gastric cancer and identify the clinicopathological factors which may explain the different prognosis of the these two types.

Materials and methods
=====================

Ethics statement
----------------

All patients provided written informed consent for their information to be stored and used in the hospital database. Study approval was obtained from independent ethics committees at Cancer Center of Sun Yat-Sen University. The study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.

Patients
--------

The medical records of 1000 patients with pathologically-confirmed gastric adenocarcinoma between January 1996 and December 2006 were retrospectively analyzed. They all received D2 resection carried out by experienced surgeons in the Cancer Center of Sun Yat-Sen University following the Japanese Gastric Cancer Association (JGCA) guidelines \[[@B11]\]. Both the proximal and distal margins are negative and at least 3 cm away from the tumor. Besides, the surgeon dissected the station D2 lymph nodes. There is no macroscopic or microscopic residual tumor. The total number of dissected lymph nodes of the 1000 gastric carcinoma patients was 16008, with an average of 18.8 ±5.3 (means±s.d.) dissected nodes per case (median 24.0, range 13--72). The number of excised lymph nodes was less than 15 in 24.2% of patients who received resection.

We excluded 82 patients (8.2%) because of missing baseline characteristics, 75 patients (7.5%) younger than 18 years old, 32 patients (3.2%) with incomplete follow-up and 6 patients (0.6%) with secondary malignancy. None of the patients received neoadjuvant treatment. The final study involved 805 patients.

The clinical features collected for subsequent analysis included gender (male or female), age at diagnosis (\<59 or ≥59 years, the median age was 59), tumor size (≤5 cm or \>5 cm, the median diameter was 5 cm), location of primary tumor (proximal or distal), histology subtypes (well + moderate differentiated adenocarcinoma or poorly + signet ring cell differentiated adenocarcinoma), Lauren classifications (diffuse type or intestinal type), anemia (yes or no), angiolymphatic invasion (yes or no), the TNM staging system (American Joint Committee on Cancer (AJCC) 7^th^ edition) (Table  [1](#T1){ref-type="table"}).

###### 

Demographics and univariate survival analysis results of the 805 gastric carcinoma patients

  **Factors**                   **Numbers**   **5 year survival rate (%)**   **P value**
  ---------------------------- ------------- ------------------------------ -------------
  Gender                                                                           
  Male                              557                   48.9                     
  female                            248                   46.1                  0.581
  Age median 59                                                                    
  ≤59                               419                   50.5                     
  \>59                              386                   45.8                  0.135
  Lauren classification                                                            
  Diffuse type                      392                   44.1                     
  Intestinal type                   356                   52.7                  0.013
  Tumor size                                                                       
  ≤5 cm                             483                   55.2                     
  \>5 cm                            322                   38.5                 \<0.001
  Anemia                                                                           
  Yes                               247                   57.4                     
  No                                558                   61.0                  0.554
  Angiolymphatic invasion                                                          
  Yes                               52                    36.5                     
  No                                753                   48.8                  0.009
  Location of tumor                                                                
  Proximal                          347                   42.5                     
  Distal                            458                   49.4                  0.017
  Number of lymph nodes                                                            
  \<15                              195                   46.9                     
  ≥15                               610                   51.4                  0.233
  Type of gastrectomy                                                              
  Proximal subtotal                 323                   45.2                     
  Distal subtotal                   386                   56.9                     
  Total                             96                    31.5                 \<0.001
  The 7^th^ T stage (AJCC)                                                         
  T1                                59                    88.1                     
  T2                                87                    67.8                     
  T3                                532                   45.3                     
  T4                                127                   27.5                 \<0.001
  The 7^th^ N stage (AJCC)                                                         
  N0                                269                   69.0                     
  N1                                125                   59.6                     
  N2                                179                   44.0                     
  N3                                232                   23.0                 \<0.001
  The 7^th^ TNM stage (AJCC)                                                       
  IA                                56                    86.3                     
  IB                                70                    76.9                     
  IIA                               96                    70.7                     
  IIB                               206                   66.2                     
  IIIA                              82                    59.5                     
  IIIB                              132                   43.7                     
  IIIC                              163                   24.3                 \<0.001

Abbreviations: *AJCC*, American Joint Committee on Cancer; *TNM*, Tumor-Node-Metastasis.

During the study period we did not have a standardized protocol for postoperative chemotherapy and (or) radiotherapy. Adjuvant therapy was considered in patients with T3-T4 classification and/or positive lymph node involvement. In the present study, only 532 (66.1%) patients completed the adjuvant chemotherapy (2--6 cycles). Agents using for chemotherapy included oxaliplatin, 5-fluorouracil, capecitabine, S-1, irinotecan, docetaxol and taxol. The median number of cycles was 4. No patients received adjuvant radiotherapy. As of May 1^st^, 2012, 403 patients had died from the disease.

Tissue samples from resected tumors were classified and staged by an experienced pathologist according to the WHO classification and the TNM staging system following general pathological guidelines. Assignment of the histologic type was based on the Lauren criteria. The intestinal type was described as a tumor with glandular architecture, resembling colonic carcinoma; the diffuse type, as a tumor composed of solitary or small clusters of cells, and lacking glandular structures. The mixed type was described as the combination of these two features. Two pathologists reviewed the original diagnostic slides in order to grade, stage and classify the tumors as intestinal or diffuse type.

Statistical analysis
--------------------

All statistical analyses were performed by Statistical Package of Social Sciences 13.0 software. P value \< 0.05 was considered to be statistically significant. The Kaplan-Meier method was used to estimate overall survival. For patients who remained alive, data were censored at the date of the last contact. Kaplan-Meier analysis with log-rank testing was used for univariate analysis. The definition of the overall survival interval was the duration between the date of diagnosis and the date of last contact. Variables showing a trend for association with survival (P \< 0.05) and variables that were known to have prognostic value were selected in the final multivariable Cox proportional hazards model, while variables that are highly associated with others were excluded from the final multivariable model. The chi-square test was used to compare the clinicopathologic data.

Results
=======

Patient demographics
--------------------

The median age of the 805 patients was 59 years (ranging from 20 to 84 years old). Among them 557 were male and 248 were female. The overall 5-year survival for the patient population was 48.2%, with a median survival of 53.4 months. The median follow-up for the entire cohort was 42.0 months (range 3.0--173.0 months). The characteristics of the 805 gastric adenocarcinoma patients and the effect of clinical features on survival are summarized in Table  [1](#T1){ref-type="table"}.

Lauren classification
---------------------

There were 396 (49.2%) patients with diffuse-type and 352 (43.7%) patients with intestinal-type carcinoma. The remaining 57 patients belonged to the mixed-type carcinoma. In the following analysis, we only included the 748 patients with the diffuse-type or intestinal-type carcinoma.

Patient characteristics of the two groups are shown in Table  [2](#T2){ref-type="table"}. Among intestinal-type carcinoma, 146 (41.5%) were younger than 60 years old compared to 246 (62.1%) of patients with diffuse-type carcinoma (P\<0.001). The ratio of male to female was significantly higher in the intestinal-type carcinoma group than that in the diffuse-type group, 3.1 vs 0.86 (P\<0.001). We divided the ten year study period into two groups, the early period: from January 1996 to December 2000, the later period: from January 2001 to December 2006. We found that the ratio between diffuse type to intestinal type decreased from 1.57 (early period) to 1.03 (later period), P=0.041. Among intestinal-type carcinomas, 55.3% of tumors were located in the proximal stomach compared to 32.9% of diffuse-type carcinomas, (P \<0.001). The mean size of tumors was about 51.6 mm for diffuse-type carcinomas and 50.2 mm for intestinal-type , P=0.268. Distribution of T-stage was significantly different between the diffuse-type and the intestinal-type (Table  [2](#T2){ref-type="table"}). Moreover, for the lymph nodes status, 41.3% of patients with intestinal-type carcinoma had no evidence of lymph nodes metastasis, while for the diffuse-type carcinoma, the rate of N0 was 28.6%. Besides, the ratio of stage I: II: III was 12.1%:37.2%: 50.7% in the diffuse-type, nevertheless, it was 18.5%: 37.7%: 43.8% in the intestinal-type, P=0.027.

###### 

Clinicopathologic features and Lauren classification

  **Characteristics**           **Total number**   **Lauren classification**   **P value**  
  ---------------------------- ------------------ --------------------------- ------------- ---------
  Age                                                                                        \<0.001
  ≤59                                 392                     246                  146      
  \>59                                356                     150                  206      
  Sex                                                                                        \<0.001
  Female                              298                     211                  87       
  Male                                450                     181                  269      
  Time period                                                                                 0.041
  1996.1--2000.12                     118                     72                   46       
  2001.1--2006.12                     630                     320                  310      
  Location of tumor                                                                          \<0.001
  Proximal                            326                     129                  197      
  distal                              422                     263                  159      
  Size                                                                                        0.268
  ≤5 cm                               453                     230                  223      
  \>5 cm                              295                     162                  133      
  The 7^th^ T stage (AJCC)                                                                   \<0.001
     T1                                61                     24                   37       
     T2                                79                     55                   24       
     T3                               532                     260                  272      
     T4                                76                     57                   19       
  The 7^th^ N stage (AJCC)                                                                   \<0.001
     N0                               259                     112                  147      
     N1                               116                     52                   64       
     N2                               161                     92                   69       
     N3                               212                     140                  72       
  The 7^th^ TNM stage (AJCC)                                                                  0.027
     I                                113                     47                   66       
     II                               280                     146                  134      
     III                              355                     199                  156      
  Histology subtype                                                                          \<0.001
  Well + Moderate                     281                      0                   281           
  Poor + signet ring cell             467                     392                  75            

Abbreviations: *AJCC*, American Joint Committee on Cancer; *TNM*, Tumor-Node-Metastasis; The analysis only includes 748 patients, and excludes 57 mixed diffuse-intestinal types.

Univariate and multivariable analyses of overall survival
---------------------------------------------------------

Both univariate and multivariable analyses were used to evaluate factors relating to overall survival. Factors of Lauren classification, tumor size, angiolymphatic invasion, location of tumor, degree of differentiation, T stage, N stage and TNM stage in the AJCC 7^th^ system were significantly associated with overall survival (Table  [1](#T1){ref-type="table"}). The 5-year overall survival rate of patients with diffuse-type and intestinal type were 44.1% and 52.7%, respectively, P=0.013 (Figure  [1](#F1){ref-type="fig"}).

![Survival curves of gastric adenocarcinoma patients with diffuse-type and intestinal-type.](1479-5876-11-58-1){#F1}

For the multivariable regression analysis, only T stage (P\<0.001), N stage (P\<0.001),tumor size (P\<0.001) and Lauren classification (P=0.003) remained independent negative predictors of survival (Table  [3](#T3){ref-type="table"}).

###### 

Multivariate analysis of overall survival in gastric carcinoma

  **Factors**               **       Characteristics**   **Hazard ratio**   **95%CI**   **P value**    
  ------------------------- ---------------------------- ------------------ ----------- -------------- ---------
  Age                       ≥59                          \<59               1.111       0.899--1.374   0.328
  Gender                    Female                       Male               1.057       0.843--1.324   0.631
  Lauren classification     Diffuse type                 Intestinal type    0.736       0.595--0.910   0.005
  Histological grade        Poorly                       Well/moderately    1.025       0.899--1.167   0.714
  Size                      \>5 cm                       ≤5 cm              1.605       1.307--1.972   \<0.001
  Location                  Proximal                     Distal             0.852       0.697--1.042   0.120
  T stage                   2/3/4                        1                  1.890       1.230--2.746   \<0.001
  N stage                   1/2/3                        0                  1.368       1.048--1.894   \<0.001
  Angiolymphatic invasion   (+)                          (−)                1.209       0.831--1.759   0.321
  Type of gastrectomy       Total                        Subtotal           1.135       0.859--1.468   0.582

*CI*, confidence interval.

Discussion
==========

In 1965, Lauren proposed a division of gastric carcinoma into two structurally distinct types, the intestinal-type and the diffuse-type \[[@B3]\]. The former was most frequently seen in men and older patients and the latter had a worse prognosis and was more frequent in women and younger patients. He proposed that these two types could account for approximately 85% of gastric carcinomas, and the remainder comprised mixed types and other less common histologies. Several studies have found that the Lauren classification is reproducible \[[@B12]-[@B16]\]. Our study confirmed the fact that patients with the diffuse-type of gastric carcinoma had poorer prognosis than patients with intestinal type (P = 0.013) in our Chinese patient population. Multivariate analysis revealed that independent prognostic factors for patients with resected gastric adenocarcinoma were TNM stage, tumor size and the Lauren classification. Our previous studies also showed that tumor size was an independent negative predictor of survival in lymph nodes negative gastric carcinoma patients \[[@B17]\]. While the histology was eliminated. Several studies have indicated that patients with intestinal-type tumors had a better outcome than those with diffuse-type tumors \[[@B8]-[@B10]\]. The two Lauren types varied in several clinical and molecular characteristics. We tried to seek the difference between these two types in the clinical features which may be responsible for the survival variation.

In our study, diffuse-type gastric carcinoma was significantly associated with younger age (p \<0.001), female preponderance (p \<0.001), distal location (P\<0.001), advanced pT (p \< 0.001), advanced pN (p \< 0.001) and advanced TNM stage (p = 0.027). Though the impact of age, gender and location as prognostic factors was still controversial, it is well accepted that advanced pN as well as advanced pT are poor prognostic factors for gastric carcinoma \[[@B17]-[@B20]\]. The higher percentage of patients with advanced pN and advanced pT subtypes in the diffuse-type gastric carcinoma as compared with the intestinal-type may contribute to the poor prognosis of patients with diffuse-type. Yamashita K et al. revealed that the more dismal prognosis of diffuse-type gastric carcinoma than intestinal-type could be explained by propensity of deeper invasion and emerging peritoneal cancer cell in the Japanese population \[[@B8]\]. In our study, we demonstrated that high percentage of advanced pN was also responsible for the poor prognosis of diffuse-type in Chinese patients with resectable gastric carcinoma.

The present study shows that both diffuse-type and intestinal-type carcinoma account for 92.9% (748/805) of gastric carcinoma in China. Diffuse-type accounted for 48.7% (392/805) of all gastric carcinomas. It was reported that intestinal type was more common in areas with a high risk for gastric carcinoma, whereas diffuse type was relatively more common in low-risk areas \[[@B13]\]. The ratio of diffuse and intestinal types of gastric carcinoma in China (1.13) was similar to the Hawaii Japanese population, which was 1.32, while in European countries, such as Finland and Portugal, intestinal type was more common (Table  [4](#T4){ref-type="table"}) \[[@B13],[@B16],[@B21],[@B22]\].

###### 

Ratio of the diffuse type to intestinal type of gastric carcinoma in different areas

  **Area**               **Diffuse type**   **Intestinal type**   **Mixed type**   **Ratio\***
  ---------------------- ------------------ --------------------- ---------------- -------------
  Our data               396                352                   57               1.13
  Hawaii Japanese ^16^   144                109                   41               1.32
  Singapore ^21^         206                405                   37               0.51
  Portugal ^22^          48                 112                   12               0.43
  Finland ^25^           537                729                   177              0.74

\* Ratio means the ratio of the diffuse type to intestinal type gastric carcinoma.

In our study we found that the intestinal-type was more frequently in males and in elderly patients, while the diffuse-type occurred more frequently in women and young patients. This results confirms the observations of others \[[@B12]-[@B15]\]. The 3.6 ma1e:female ratio for the intestinal type and 0.86 ratio for diffuse tumors in our study is comparable to that noted in Fukuoka, Japan , where they were 2.60 and 0.5 respectively \[[@B23]\], and in Hawaii Japanese, where these ratio were 2.39 and 0.86 respectively \[[@B18]\].

In China, not all the patients would go to the same hospital during the course of treatment, maybe after recurrence they would transfer to the local hospital or quit treatment. We tried to get the data of recurrence but some of the patients forgot the date of recurrence. That is why we don't analyze the recurrence free survival.

In our previous study, we showed that as the age increased there was a steady increasing in the proportion of male and steady decreasing of female \[[@B24]\]. Similarly, we presently also found a steady increasing in the ratio between male and female as the age increased. This suggests a positive relationship between the age and the male: female ratio, however the exact nature of the correlation between gender, age and Lauren classifications warrants further study.

In our study, we found a decrease in the ratio between diffuse type to intestinal type over time from 1.57 (from January 1996 to December 2000) to 1.03 (from January 2001 to December 2006), P=0.041. However, Pekka A et al. found that in a Finland based population,the ratio of diffuse-type to intestinal-type increased over time suggesting differences in the epidemiologic shift of gastric carcinomas between Eastern and Western populations \[[@B25]\].

The limitation of current study is its retrospective methodology from a single-institution experience. The impact of various treatments related outcome could not be fully evaluated. Moreover, it is inaccurate to analyze the recurrence free interval. External validation by using other large database for evaluating the prognostic effect of Lauren classification would be of value to further explore the mechanism of different prognosis between diffuse-type and intestinal-type gastric carcinoma.

Conclusion
==========

The authors are not aware of any previous studies which address the clinicopathological characteristics and prognostic impact of the Lauren classification in patients with resectable gastric cancer in China. In this retrospective study conducted with 805 patients with gastric adenocarcinoma we submit the following conclusions: 1) The combination of TNM staging with Lauren classification and tumor size are the most meaningful prognostic factors. 2) Advanced pN as well as advanced pT appear to account for the poor prognosis of diffuse-type in Chinese patients with resectable gastric carcinoma.
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